Clinical Trials

Eczema Clinical Trials

The Northwestern Medicine Multidisciplinary Eczema Center (NMEC) is conducting multiple clinical trials under the direction of the clinical trials unit (CTU) in the Department of Dermatology at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago. 

The CTU has an outstanding track record, having performed more than sixty clinical studies related to atopic dermatitis and a dozen studies related to atopic dermatitis in adults in the past decade. NMEC is currently conducting two clinical trials for leading-edge treatments for eczema (atopic dermatitis), enrolling patients from the greater Chicago area.

Current studies

Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to Severe-Atopic Dermatitis
For: Individuals ages 18 and up, diagnosed with moderate-severe atopic dermatitis
Duration: 6 months, study visits approximately 1x/month
Principal investigator: Jonathan Silverberg, MD
Study coordinator: Erin Ibler, MD (erin.ibler@northwestern.edu)

learn more at clinicaltrials.gov

Study: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
For: Individuals ages 12 and up, diagnosed with moderate atopic dermatitis
Duration: 5 months total–weekly visits for 3 weeks then monthly visits
Clinical trial #: 203121
Principal investigator (PI): Amy Paller, MD
Co-PI: Jonathan Silverberg, MD
Study coordinator: Erin Ibler, MD (erin.ibler@northwestern.edu)

learn more at clinicaltrials.gov

More information about current studies is soon to follow.

Previous studies

Our clinical trials unit has much experience in clinical trials of novel treatments for atopic dermatitis. Some of our previous clinical trials include:

• Apremilast (Phase II): A novel oral medication aimed at providing targeted treatment of atopic dermatitis.
• Dupilumab (Phase II): A novel injectable medication ("biologic") aimed at providing targeted treatment of atopic dermatitis.
• Lebrikizumab (Phase II): Also a novel injectable medication ("biologic) aimed at providing target treatment of atopic dermatitis
• APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. The purpose of this study was to gain knowledge about the long-term safety of the use of tacrolimus ointment/Protopic® for treating atopic dermatitis.